

Microarray Analysis of Gene Expression Profiles in Response to Treatment with Melatonin in Lipopolysaccharide Activated RAW 264.7 Cells

Ju Yeon Ban^{1,*}, Bum Sik Kim^{2,*}, Soo Cheol Kim², Dong Hwan Kim³, and Joo-Ho Chung⁴

¹Department of Pharmacology and Institute of Tissue Regeneration Engineering (ITREN), College of Dentistry, Dankook University, Cheonan 330-714, Departments of ²Thoracic and Cardiovascular Surgery, ³Physical Medicine and Rehabilitation, ⁴Pharmacology and Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul 130-701, Korea

Melatonin, which is the main product of the pineal gland, has well documented antioxidant and immune-modulatory effects. Macrophages produce molecules that are known to play roles in inflammatory responses. We conducted microarray analysis to evaluate the global gene expression profiles in response to treatment with melatonin in lipopolysaccharide (LPS) activated RAW 264.7 macrophage cells. In addition, eight genes were subjected to real-time reverse transcription polymerase chain reaction (RT-PCR) to confirm the results of the microarray. The cells were treated with LPS or melatonin plus LPS for 24 hr. LPS induced the up-regulation of 1073 genes and the down-regulation of 1144 genes when compared to the control group. Melatonin pretreatment of LPS-stimulated RAW 264.7 cells resulted in the down regulation of 241 genes and up regulation of 164 genes. Interestingly, among genes related to macrophage-mediated immunity, LPS increased the expression of seven genes (*Adora2b*, *Fcgr2b*, *Cish*, *Cxcl10*, *Clec4n*, *Il1a*, and *Il1b*) and decreased the expression of one gene (*Clec4a3*). These changes in expression were attenuated by melatonin. Furthermore, the results of real-time PCR were similar to those of the microarray. Taken together, these results suggest that melatonin may have a suppressive effect on LPS-induced expression of genes involved in the regulation of immunity and defense in RAW 264.7 macrophage cells. Moreover, these results may explain beneficial effects of melatonin in the treatment of various inflammatory conditions.

Key Words: Macrophages, Melatonin, Microarray, Lipopolysaccharide

INTRODUCTION

Inflammation is a complex phenomenon that involves numerous mediators that trigger a number of biological effects that are crucial to the host's normal defense against insults, pathogens or stress [1,2]. If the inflammatory response is not tightly regulated, chronic inflammation occurs, which results in a variety of pathologies, including cancer and neurodegenerative diseases [3,4]. Macrophages play a central role in mediating many different immunopathological phenomena during inflammation. Inflammatory stimulants such as lipopolysaccharide (LPS) can activate macrophages to produce a variety of pro-inflammatory cytokines including interleukin-1 β (IL-1 β), IL-6, and tumor necrosis factor- α (TNF- α), as well as other inflammatory mediators such as prostaglandins and nitric oxide (NO) [5-7].

Melatonin (*N*-acetyl-5-methoxytryptamine) is an indole-

amine that is primarily produced in the pineal gland during the dark phase. Melatonin influences circadian rhythms and seasonal environmental changes, and is associated with adjustments of physiology of animals to seasonal environmental changes [8]. Melatonin has also been shown to act as a potent antioxidant and free radical scavenger, protecting against a number of radical species in both in vivo and in vitro models of oxidative stress [9]. Melatonin protects against oxidative stress related processes in experimental models of ischemia/reperfusion, aging and neurodegenerative disorders. It has recently been suggested that melatonin is able to counteract the increase in LPS-induced levels of proinflammatory cytokines such as TNF, IL-12, and interferon (IFN)- γ , whereas it increases the production of the anti-inflammatory cytokines IL-10 [10]. The anti-inflammatory actions of melatonin have been observed in experimental animals as well in humans [11]. In this study, a microarray assay was conducted to determine which genes are differentially expressed in response to melatonin in LPS activated macrophages. The results of the microarray analysis were then confirmed by real-time reverse

Received January 3, 2011, Revised February 8, 2011,
Accepted February 8, 2011

Corresponding to: Joo-Ho Chung, Department of Pharmacology, School of Medicine, Kyung Hee University, Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Korea. (Tel) 82-2-961-0303, (Fax) 82-2-968-0560, (E-mail) jhchung@khu.ac.kr

*Equally contributed to first author.

ABBREVIATIONS: IL, interleukin; LPS, lipopolysaccharide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NO, nitric oxide; RT-PCR, reverse transcription polymerase chain reaction; TNF- α , tumor necrosis factor- α .

transcription polymerase chain reaction (RT-PCR).

METHODS

Cell culture

RAW 264.7 macrophage cells were cultured in Dulbecco's modified Eagle's medium (DMEM) media with 10% fetal bovine serum (FBS), 1% penicillin and 1% streptomycin. The cells were then maintained in a humidified atmosphere that contained 5% CO₂ at 37°C. Next, the cells were pre-treated with melatonin for 30 min, and after which they were treated with 1 µg/ml of LPS for 24 h.

MTT assay for cell viabilities

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded in triplicate at a concentration of 1×10⁵ cells per well on a 48-well plate. In a dose-dependent test, RAW 264.7 cells were treated with melatonin at concentrations of 50, 100, and 500 µM for 24 h. After MTT (Sigma, St Louis, MO, USA) was added to each group, the cells were incubated for 4 h. The cells were then further incubated for 1 h in the solution in which the MTT was dissolved. The viability was then measured with a microplate reader (Bio-Tek, Winooski, VT, USA) at a test wavelength of 595 nm with a reference wavelength of 690 nm. The optical density (O.D.) was calculated as the difference between the reference wavelength and the test wavelength. The percent viability was calculated as (O.D. of drug-treated sample/O.D. of untreated sample)×100.

Nitrite assay

After pre-incubating RAW 264.7 cells (1×10⁵ cells/ml) with LPS for 24 h, the quantity of nitrite in the culture medium was measured and used as an indicator of NO production. Briefly, 50 µl of cell culture medium were mixed with 100 µl of Griess reagent (0.5% sulfanilic acid, 0.002% *N*-1-naphthyl-ethylenediamine dihydrochloride, 14% glacial acetic acid) (Promega, Madison, WI, USA) and then incubated at room temperature for 10 min. Next, the absorbance at 540 nm was measured with an ELISA plate reader (Bio-Tek, Winooski, VT, USA), using sodium nitrite as the standard. Fresh culture medium was used as a blank in every experiment.

RNA preparation

Total RNA was extracted using Trizol (Invitrogen Life Technologies, Carlsbad, USA) and then purified using RNeasy columns (Qiagen, Valencia, USA) according to the manufacturers' protocol. After being subjected to DNase digestion and clean-up procedures, the RNA samples were quantified, and stored at -80°C until use. For quality control, the RNA purity and integrity were evaluated by denaturing gel electrophoresis, OD 260/280 ratio, and analyzed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA).

Labeling and purification

Total RNA was amplified and purified using an Ambion

Illumina RNA amplification kit (Ambion, Austin, USA) to yield biotinylated cRNA according to the manufacturer's instructions. Briefly, 550 ng of total RNA were reverse-transcribed to cDNA using a T7 oligo (dT) primer. Second-strand cDNA was synthesized, transcribed *in vitro*, and labeled with biotin-NTP. After purification, the cRNA was quantified using a ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA).

Hybridization and data export

A total of 750 ng of labeled cRNA samples were hybridized to each mouse-8 expression bead array for 16~18 h at 58°C, according to the manufacturer's instructions (Illumina, Inc., San Diego, CA, USA). Detection of an array signal was conducted using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the bead array manual. Arrays were scanned with an Illumina bead array reader confocal scanner according to the manufacturer's instructions. Array data export processing and analysis was performed using Illumina BeadStudio v3.1.3 (Gene Expression Module v3.3.8).

Raw data preparation and statistical analysis


The quality of hybridization and overall chip performance were monitored by visual inspection of both internal quality control checks and the raw scanned data. Raw data were extracted using the software provided by the manufacturer Illumina GenomeStudio v2009.2 (Gene Expression Module v3.3.8). Array data were filtered by detection $p < 0.05$ (similar to signal to noise) in all samples (we applied a filtering criterion for data analysis; higher signal value was required to obtain a detection $p < 0.05$). The selected gene signal value was transformed by logarithm and normalized by the quantile method. Comparative analysis was carried out using a LPE-test adjusted FDR p value and fold-change. Biological ontology-based analyses were performed using the Panther database (<http://www.pantherdb.org>).

Real-time RT-PCR

For the LightCycler reaction, a mastermix of the following reaction components was prepared to the indicated end-concentrations: 2.2 µl water, 0.4 µl forward primer, 0.4 µl reverse primer and 5 µl SYBR premix EX taq (Takara, RR041A). LightCycler mastermix (8 µl) was added to the LightCycler glass capillaries and 1 µl cDNA was added as the PCR template. The capillaries were then closed, centrifuged and placed into the LightCycler rotor. The following LightCycler experimental run protocol was used: denaturation program (95°C for 3 min), amplification program repeated 50 times (95°C for 5 sec, 60°C for 10 sec, 72°C for 30 sec), melting curve program (60~95°C with a heating rate of 0.1°C per second and a continuous fluorescence measurement) and finally a cooling step to 40°C for 30 sec. For the mathematical model, it was necessary to determine the crossing points (CP) for each transcript. CP is defined as the point at which the fluorescence rises appreciably above the background fluorescence. The Fit Point Method must be performed using the LightCycler software 3.3 (Roche Diagnostics), with CP being measured at a constant fluorescence level. The primers specific for the studied genes studied are listed in Table 1.

Table 1. Primer sequences of genes applied in real-time RT-PCR

Gene	Primers
Adora2b	Sense: 5'- CTATGCCTACAGGAACCGAGACT -3' Antisense: 5'- GTCAGCCAGACTTGTGTAACCTCC-3'
Cish	Sense: 5'- GTACAGGGATCTTGTCCCTTGC-3' Antisense: 5'- GGCTGTAATAGAACCCAGTACC-3'
Clec4a3	Sense: 5'- ACTCCTCAGACATCGACACAGAC-3' Antisense: 5'- ACAGCTCCAGACTTTGTCTTCC-3'
Clec4n	Sense: 5'- GTCCCTGAGTCGTATTTTGGAG-3' Antisense: 5'-CTGACACCATAGTCCCTTCACTG-3'
Cxcl10	Sense: 5'-CTCTCTCCATCACTCCCTTTAC -3' Antisense: 5'-ACTTAGAACTGACGAGCCTGAGC -3'
Fcgr2b	Sense: 5'-GAACTCTTCTACCCAGTGGTTCC -3' Antisense: 5'-GCAGTAGTAGTCCCCTGTTGAC -3'
Il1a	Sense: 5'- CCAGATCAGCACCTTACACCTAC-3' Antisense: 5'-AGGTCGGTCTCACTACCTGTGAT -3'
Il1b	Sense: 5'-CCTAAAGTATGGGCTGGACTGT -3' Antisense: 5'-CTAGAGAGTGTGCCAATGTCC-3'

**Fig. 1.** Cytotoxicity of melatonin was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. RAW 264.7 macrophage cells were exposed to melatonin at 0, 50, 100, and 500 µM in the absence or presence of LPS for 24 h. The results are presented as the mean±S.E.M. LPS, lipopolysaccharide.


RESULTS

Cytotoxicity of melatonin in RAW 264.7 cells

To determine the cytotoxic effects of melatonin in RAW 264.7 macrophage cells, cells were incubated with various concentrations of melatonin (50, 100 and 500 µM) for 24 h. In an MTT assay, the viabilities of RAW 264.7 cells exposed to melatonin for 24 h were 100.00±0.12%, 100.18±0.19%, 99.74±0.61%, and 99.75±0.20%, respectively (Fig. 1), indicating that treatment with melatonin did not have cytotoxic effects in RAW 264.7 cells. These results show that melatonin can be used safely.

Effects of melatonin on the LPS-induced production of NO

The effect of melatonin on NO production in LPS-activated RAW 264.7 cells was tested to investigate its anti-in-

**Fig. 2.** The effects of melatonin on nitrite production. RAW 264.7 cells were pretreated with 50, 100, and 500 µM of melatonin and then treated with lipopolysaccharides (1.0 µg/ml). The media were harvested 24 h later and assayed for nitrite production. Data are the means±S.E.M. LPS, lipopolysaccharide; Mel, melatonin. ^{##}p<0.01 compared to control, ^{**}p<0.01 compared to LPS.

flammatory effects. The amount of nitrite accumulated in the culture medium was estimated using Griess reagent as an index for NO. After LPS (1.0 µg/ml) treatment of RAW 264.7 cells for 24 h, the nitrite concentration in the medium increased by about 13-fold (3.90±1.08 versus 51.40±1.51 µM). As shown in Fig. 2, when cells were treated with various concentrations of melatonin, NO production decreased in a dose-dependent manner. Melatonin treatment at 100 and 500 µM was found to suppress NO production to 41.77±1.44 and 32.69±1.10 µM, respectively (p<0.01).

Analysis of microarray expression data

We conducted gene expression analysis using a cDNA microarray of the mouse genome 24k to search for genes regulated by LPS, melatonin and melatonin plus LPS treatment in RAW 264.7 cells. To normalize the intensity ratio of each gene expression pattern, quantile normalization was used. After normalizing the data, the cut-off value was set at a fold-change of ±2 (p<0.05). LPS treatment resulted in up-regulation of 1073 genes and down-regulation of 1144 genes. The melatonin treatment caused up-regulation of 12 genes and down-regulation of 85 genes. Melatonin plus LPS treatment resulted in up-regulation of 164 genes and down-regulation of 241 genes. To characterize the genes regulated by LPS and melatonin, the genes were grouped by biological function (<http://www.pantherdb.org>). Biological processes involved in genes regulated by LPS are shown in Fig. 3A, while those involved in genes regulated by melatonin plus LPS are shown in Fig. 3B.

Gene expression profiles of melatonin plus LPS treated cells

Of 31 biological processes regulated by LPS treatment, the most significant are immunity and defense-related genes. Overall, 162 genes were differentially expressed in the LPS-treated group when compared to the normal group, while 51 genes exhibited differential expression levels between the LPS and melatonin plus LPS-treated groups (data not shown).




Fig. 3. Functional analysis of genes selected using the Panther database. (A) Functional categories of genes regulated by LPS treatment in RAW 264.7 macrophage cells. (B) Functional categories of genes regulated by melatonin pretreatment in LPS-stimulated RAW 264.7 macrophage cells.

Table 2. List of "macrophage-mediated immunity" genes regulated by lipopolysaccharide treatment in RAW 264.7 macrophage cells

Gene symbol	Gene name	Fold change
<i>S100a4</i>	S100 calcium binding protein A4	-8.88
<i>Ltc4s</i>	Leukotriene C4 synthase	-6.83
<i>Clec4a3</i>	C-type lectin domain family 4, member a3	-2.83
<i>Clec10a</i>	C-type lectin domain family 10, member A	-2.38
<i>Alox5ap</i>	Arachidonate 5-lipoxygenase activating protein	-2.23
<i>Lgals3bp</i>	Lectin, galactoside-binding, soluble, 3 binding protein	-2.1
<i>Adora2b</i>	Adenosine A2b receptor	2.17
<i>Ddt</i>	D-dopachrome tautomerase	2.75
<i>Clec4d</i>	C-type lectin domain family 4, member d	3
<i>Gbp1</i>	Guanylate binding protein 1	3.07
<i>Il10</i>	Interleukin 10	3.24
<i>Fcgr2b</i>	Fc receptor, IgG, low affinity IIb	3.54
<i>Gbp2</i>	Guanylate binding protein 2	4.27
<i>Gbp3</i>	Guanylate binding protein 3	4.4
<i>Clec4e</i>	C-type lectin domain family 4, member e	5.9
<i>Cish</i>	Cytokine inducible SH2-containing protein	8.19
<i>Cxcl10</i>	Chemokine (C-X-C motif) ligand 10	10.5
<i>Clec4n</i>	C-type lectin domain family 4, member n	12.03
<i>S100a8</i>	S100 calcium binding protein A8 (calgranulin A)	41.32
<i>Il1a</i>	Interleukin 1 alpha	76.72
<i>Il1b</i>	Interleukin 1 beta	148.59
<i>Cxcl2</i>	Chemokine (C-X-C motif) ligand 2	328.7

We focused on genes related to macrophage-mediated immunity. As shown in Table 2, *S100a4*, *Ltc4s*, *Clec4a3*, *Mgl1*, *Alox5ap* and *Lgals3bp* were down-regulated, while *Adora2b*, *Ddt*, *Clec4d*, *Gbp1*, *Il10*, *Fcgr2b*, *Gbp2*, *Gbp3*, *Clec4e*, *Cish*, *Cxcl10*, *Clec4n*, *Clecsf9*, *S100a8*, *Il1a*, *Il1b* and *Cxcl2* were up-regulated in the LPS-treated group. Conversely, *Colec12*, *Cxcl4* and *Clec4a3* were up-regulated, while *Cxcl10*, *Il1b*, *Adora2b*, *Fcgr2b*, *Il1a*, *Clec4n* and *Cish*

Table 3. List of "macrophage-mediated immunity" genes regulated by melatonin pretreatment in lipopolysaccharide-stimulated RAW 264.7 macrophage cells

Gene symbol	Gene name	Fold change
<i>Cxcl10</i>	Chemokine (C-X-C motif) ligand 10	-7.54
<i>Il1b</i>	Interleukin 1 beta	-3.87
<i>Adora2b</i>	Adenosine A2b receptor	-3.13
<i>Fcgr2b</i>	Fc receptor, IgG, low affinity IIb	-3
<i>Il1a</i>	Interleukin 1 alpha	-2.73
<i>Clec4n</i>	C-type lectin domain family 4, member n	-2.61
<i>Cish</i>	Cytokine inducible SH2-containing protein	-2.46
<i>Colec12</i>	Collectin sub-family member 12	2.21
<i>Cxcl4</i>	Chemokine (C-X-C motif) ligand 4	2.22
<i>Clec4a3</i>	C-type lectin domain family 4, member a3	2.5

were down-regulated in the melatonin plus LPS-treated group when compared to the LPS-treated group (Table 3). Interestingly, the *Adora2b*, *Fcgr2b*, *Cish*, *Cxcl10*, *Clec4n*, *Il1a* and *Il1b* genes were significantly up-regulated in the LPS-treated group, whereas they were down-regulated by treatment with melatonin. Moreover, the *Clec4a3* gene was down-regulated in the LPS-treated group, but was up-regulated in response to treatment with melatonin.

Validation of microarray results by real-time RT-PCR

To verify the gene expression profiles generated by the microarray analysis, expression pattern clustering was conducted using real-time RT-PCR. As shown in Fig. 4, real-time RT-PCR results were in agreement with the microarray data. LPS enhanced the mRNA expressions of *Adora2b*, *Fcgr2b*, *Cish*, *Cxcl10*, *Clec4n*, *Il1a* and *Il1b*, while it repressed the expression of *Clec4a3*. These changes in LPS-induced gene expression were also reversed by melatonin pretreatment. Overall, the microarray results and real-time PCR results were found to be very similar.




Fig. 4. Validation of microarray results using real-time RT-PCR. Relative expression of each gene in the control was designated as 1, values are mean±S.E.M. LPS, lipopolysaccharide; Mel, melatonin. [#]p<0.05, ^{##}p<0.01 compared to control, ^{*}p<0.05, ^{**}p<0.01 compared to LPS.

DISCUSSION

In a previous study, we demonstrated that melatonin inhibited LPS-induced CC chemokine subfamily gene expression in human peripheral blood mononuclear cells using a CombiMatrix 2k Human Inflammation chip [12]. In the present study, we investigated the effect of melatonin on global gene expression in LPS-stimulated RAW 264.7 cells, using a 24K cDNA microarray. MTT assay revealed that melatonin showed no cytotoxic effects in RAW 264.7 cells. Melatonin significantly inhibited LPS-induced NO production in RAW 264.7 cells. The results of the microarray analysis showed that 2217 genes were differentially expressed by RAW 264.7 cells following LPS treatment (1073 up-regulated and 1144 down-regulated). Melatonin plus LPS treatment resulted in differential expression of 405 genes (164 up-regulated and 241 down-regulated) when compared to the LPS-treated group. However, this study only focused on genes belonging to categories of macrophage-mediated immunity. Treatment with melatonin induced the down-regulation of seven genes that up-regulated by LPS (*Adora2b*, *Fcgr2b*, *Cish*, *Cxcl10*, *Clec4n*, *Il1a* and *Il1b* genes), whereas it caused the up-regulation of one down-regulated gene (*Clec4a3*).

The *ADORA2B* (adenosine A2b receptor) gene encodes an adenosine receptor that is a member of the G protein-coupled receptor superfamily. Adenosine is released in response to various stimuli, including hypoxia, tissue damage or chronic inflammation [13]. Adenosine signals through four subtypes of adenosine receptors (A1, A2a, A2b, and A3) that are ubiquitously expressed on various hematopoietic and non-hematopoietic cells. Each type of adenosine receptor exhibits a distinct pharmacological and physiological profile [14]. Adenosine receptors A2a and A2b have been recognized as important mediators in inflammatory models [15,16]. Additionally, Schingnitz et al. [17] showed that LPS treatment induced *Adora2b* transcription and corresponding protein expression in *in vivo* and *in vitro* studies. In the present study, LPS induced an increase in the expression of *Adora2b* (2.17 fold), while melatonin pretreatment inhibited the expression of LPS-stimulated *Adora2b* gene up-regulation (-3.13 fold).

FCGR2B is a low affinity receptor for the Fc region of immunoglobulin gamma complexes that is involved in the phagocytosis of immune complexes and the regulation of antibody production by B-cells [18]. In this study, *Fcgr2b* increased 3.54 fold in response to LPS treatment when compared to the control; however, its expression was decreased by melatonin treatment.

CISH contains a SH2 domain and a SOCS box domain. Thus, the protein belongs to the cytokine-induced STAT inhibitor (CIS) family, which is also known as a suppressor of the cytokine signaling (SOCS) or STAT-induced STAT inhibitor (SSI). CIS family members are known to be cytokine-inducible negative regulators of cytokine signaling. Jin et al. [19] reported that the expression levels of most SOCS genes, such as *CISH*, *SOCS1-5* and *SOCS9*, were increased after LPS challenge, indicating that they are involved in inflammatory response. In the present study, *Cish* expression was highly increased (8.19-fold) by LPS treatment, but decreased in response to melatonin treatment.

The *CXCL10* gene encodes a chemokine of the CXC subfamily and a ligand for the receptor *CXCR3*. The binding of this protein to *CXCR3* results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell

migration, and modulation of adhesion molecule expression. *CXCL10* is induced by LPS in RAW macrophage cells [20]. Feferman et al. [21] found increased expression of *Cxcl10* and its receptor, *Cxcr3*, in lymph node cells of rats with experimental autoimmune myasthenia gravis. In the present study, *Cxcl10* expression increased 10.50 fold in response to LPS treatment, but decreased -7.54 fold in response to melatonin treatment. *Cxcl2* was also highly up-regulated (328.70 fold) by LPS, but was not affected by melatonin treatment.

Il1a and *Il1b* are members of the interleukin 1 cytokine family, which are pleiotropic cytokines involved in various immune responses, inflammatory processes and hematopoiesis. These cytokines are synthesized by a variety of cell types, including activated macrophages, stimulated B lymphocytes, and fibroblasts, and are potent mediators of inflammation and immunity [22]. Moreover, *Il1a* and *Il1b* polymorphisms are associated with various inflammatory diseases, such as periodontitis, osteomyelitis, and Bowel disease [23-25]. In this study, *Il1a* and *Il1b* were highly up-regulated by LPS, but down-regulated by melatonin treatment.

In conclusion, our results showed that melatonin decreased the expression of various genes related to the macrophage-mediated immunity that occurs in LPS stimulated RAW 264.7 cells. In addition, we confirmed these microarray data using real-time PCR. These results suggest that melatonin possesses anti-inflammatory properties, and is involved in the regulation of immunity and defense related genes that act as key mediators in various inflammatory processes.

ACKNOWLEDGEMENTS

This research was supported by the Program of Kyung Hee University for the Young Researcher of Medical Science in 2007 (KHU-20071509).

REFERENCES

1. Nathan C. Points of control in inflammation. *Nature*. 2002;420:846-852.
2. Foster SL, Medzhitov R. Gene-specific control of the TLR-induced inflammatory response. *Clin Immunol*. 2009;130:7-15.
3. Balkwill F, Coussens LM. Cancer: an inflammatory link. *Nature*. 2004;431:405-406.
4. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS--a dual role? *Exp Neurol*. 2004;187:1-10.
5. Gordon S. Alternative activation of macrophages. *Nat Rev Immunol*. 2003;3:23-35.
6. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol*. 2008;8:958-969.
7. Kopydlowski KM, Salkowski CA, Cody MJ, van Rooijen N, Major J, Hamilton TA, Vogel SN. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. *J Immunol*. 1999;163:1537-1544.
8. Reiter RJ. Melatonin: clinical relevance. *Best Pract Res Clin Endocrinol Metab*. 2003;17:273-285.
9. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. *Curr Top Med Chem*. 2002;2:181-197.
10. Carrillo-Vico A, Lardone PJ, Najj L, Fernández-Santos JM,

- Martín-Lacave I, Guerrero JM, Calvo JR.** Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. *J Pineal Res.* 2005;39:400-408.
11. **Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cordaro S, Corona G, Trimarchi G, Barberi I.** Effects of melatonin treatment in septic newborns. *Pediatr Res.* 2001;50:756-760.
 12. **Park HJ, Kim HJ, Ra J, Hong SJ, Baik HH, Park HK, Yim SV, Nah SS, Cho JJ, Chung JH.** Melatonin inhibits lipopolysaccharide-induced CC chemokine subfamily gene expression in human peripheral blood mononuclear cells in a microarray analysis. *J Pineal Res.* 2007;43:121-129.
 13. **Blackburn MR, Lee CG, Young HW, Zhu Z, Chunn JL, Kang MJ, Banerjee SK, Elias JA.** Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. *J Clin Invest.* 2003;112:332-344.
 14. **Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M.** Nomenclature and classification of purinoceptors. *Pharmacol Rev.* 1994;46:143-156.
 15. **Reutershan J, Cagnina RE, Chang D, Linden J, Ley K.** Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. *J Immunol.* 2007;179:1254-1263.
 16. **Eckle T, Grenz A, Laucher S, Eltzschig HK.** A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. *J Clin Invest.* 2008;118:3301-3315.
 17. **Schingnitz U, Hartmann K, Macmanus CF, Eckle T, Zug S, Colgan SP, Eltzschig HK.** Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. *J Immunol.* 2010;184:5271-5279.
 18. **Takai T.** Fc receptors and their role in immune regulation and autoimmunity. *J Clin Immunol.* 2005;25:1-18.
 19. **Jin HJ, Shao JZ, Xiang LX, Wang H, Sun LL.** Global identification and comparative analysis of SOCS genes in fish: insights into the molecular evolution of SOCS family. *Mol Immunol.* 2008;45:1258-1268.
 20. **Kim BH, Lee KH, Chung EY, Chang YS, Lee H, Lee CK, Min KR, Kim Y.** Inhibitory effect of chroman carboxamide on interleukin-6 expression in response to lipopolysaccharide by preventing nuclear factor-kappaB activation in macrophages. *Eur J Pharmacol.* 2006;543:158-165.
 21. **Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC.** Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. *J Immunol.* 2005;174:5324-5331.
 22. **Lord PC, Wilmoth LM, Mizel SB, McCall CE.** Expression of interleukin-1 alpha and beta genes by human blood polymorphonuclear leukocytes. *J Clin Invest.* 1991;87:1312-1321.
 23. **Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, Wilson TG Jr, Higginbottom FL, Duff GW.** The interleukin-1 genotype as a severity factor in adult periodontal disease. *J Clin Periodontol.* 1997;24:72-77.
 24. **Asensi V, Alvarez V, Valle E, Meana A, Fierer J, Coto E, Carton JA, Maradona JA, Paz J, Dieguez MA, de la Fuente B, Moreno A, Rubio S, Tuya MJ, Sarasúa J, Llamas S, Arribas JM.** IL-1 alpha (-889) promoter polymorphism is a risk factor for osteomyelitis. *Am J Med Genet A.* 2003;119A:132-136.
 25. **Mwantembe O, Gaillard MC, Barkhuizen M, Pillay V, Berry SD, Dewar JB, Song E.** Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease (IBD) and in control individuals. *Immunogenetics.* 2001;52:249-254.